2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 978-991

  Van Der Heijde, Désirée ^a   Ramiro, Sofia ^a   Landewé, Robert ^b,c   Baraliakos, Xenofon ^d   Van Den Bosch, Filip ^e   Sepriano, Alexandre ^a,f   Regel, Andrea ^d   Ciurea, Adrian ^g   Dagfinrud, Hanne ^h   Dougados, Maxime ^i,j   Van Gaalen, Floris ^a   Géher, Pál ^k   Van Der Horst Bruinsma, Irene ^l   Inman, Robert D ^m   Jongkees, Merryn ⁿ   Kiltz, Uta ^d   Kvien, Tore K ^h   Machado, Pedro M ^o   Marzo Ortega, Helena ^p,q   Molto, Anna ^i,j   Navarro Compàn, Victoria ^r   Ozgocmen, Salih ^s   Pimentel Santos, Fernando M ^f   Reveille, John ^t   Rudwaleit, Martin ^u,v,w   Sieper, Jochen ^w   Sampaio Barros, Percival ^x   Wiek, Dieter ^y   Braun, Jürgen ^d   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Amsterdam Rheumatology and Immunology Center   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f NOVA MEDICAL SCHOOL   (Portugal)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h DIAKONHJEMMET HOSPITAL   (Norway)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j PARIS DESCARTES UNIVERSITY   (France)

^k SEMMELWEIS UNIVERSITY   (Hungary)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ Patient Partner   (Netherlands)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^q UNIVERSITY OF LEEDS   (United Kingdom)

^r HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^s ERCIYES UNIVERSITY   (Turkey)

^t UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^u Klinikum Bielefeld   (Germany)

^v GHENT UNIVERSITY   (Belgium)

^w CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^x UNIVERSITY OF SÃO PAULO   (Brazil)

^y EULAR PARE Patient Research Partner and EULAR PARE   (Germany)

more..

Author keywords

DMARDs (biologic); NSAIDs; Physcial therapy; Spondyloarthritis; Treatment

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 17 INHIBITOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALAZOSULFAPYRIDINE; SECUKINUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; INTERLEUKIN 17; TUMOR NECROSIS FACTOR;

AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRALGIA; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG SAFETY; DRUG TOLERANCE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; JOINT STIFFNESS; MEDICAL DECISION MAKING; PATIENT EDUCATION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SACROILIITIS; SOCIAL PARTICIPATION; SPONDYLARTHRITIS; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; DRUG SUBSTITUTION; TREATMENT OUTCOME;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; DRUG SUBSTITUTION; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-17; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85011039422     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210770     Document Type: Article

References (112)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
2. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, et al. Prevalence of extra-Articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-Analysis. Ann Rheum Dis 2015;74:65-73.
3. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
4. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
5. Sieper J, van der Heijde D. Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum 2013;65:543-51.
6. van den Berg R, Lenczner G, Feydy A, et al. Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs. Results from the DESIR cohort. Arthritis Rheumatol 2014;66:2403-11.
7. Sepriano A, Rudwaleit M, Sieper J, et al. Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? Ann Rheum Dis 2016;75:1262-3.
8. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM361563.pdf
9. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm361566.pdf
10. Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:1369-74.
11. Deodhar A, Strand V, Kay J, et al. The term non-radiographic axial spondyloarthritis is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis 2016;75:791-4.
12. Davis JC, Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
13. Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014;66:2091-102.
14. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
15. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-22.
16. Inman RD, Davis JC Jr, Heijde Dv, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
17. Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2015;67:2702-12.
18. European Medicines Agency. Concept paper on clinical investigation of medicinal products for the treatment of axial spondyloarthritis. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/04/WC500185187.pdf
19. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-Tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
20. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
21. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
22. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
23. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
24. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
25. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
26. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534-48.
27. Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2016. doi:10.1136/annrheumdis-2016-210023. [Epub ahead of print 31 Aug 2016]
28. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 2014;73:39-47.
29. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
30. Appraisal of guidelines for research & evaluation II. http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-And-23-item-Instrument-2009-UPDATE-2013.pdf
31. Ramiro S, Sepriano A, Chatzidionysiou A, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2016.
32. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, 2008.
33. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37.
34. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
35. van den Berg R, Baraliakos X, Braun J, et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1388-96.
36. Baraliakos X, van den Berg R, Braun J, et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1378-87.
37. Oxford Centre for Evidence-Based Medicine. The Oxford, 2009. Levels of Evidence (updated in 2012). http://www.cebm.net/oxford-centre-evidence-based-medicinelevels-evidence-march-2009/
38. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 2014;73:3-5.
39. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis ( part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
40. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
41. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis 2016;75:965-73.
42. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
43. Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
44. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
45. Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum 2015;44:556-62.
46. The international classification of functioning disability and health. Geneva: World Health Organization, 2001.
47. Boonen A, Braun J, van der Horst Bruinsma IE, et al. ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 2010;69:102-7.
48. Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2015;74:830-5.
49. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73:1455-61.
50. Landewé R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863-7.
51. Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 2016;75:2114-18.
52. van der Heijde D, Joshi A, Pangan AL, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 2016;55:80-8.
53. Westhovens R, Annemans L. Costs of drugs for treatment of rheumatic diseases. RMD Open 2016;2:e000259.
54. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44.
55. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-18.
56. van der Heijde D, Maksymowych W, Landewé R, et al. Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of RAPID-AxSpA study. Ann Rheum Dis 2013;72:515.
57. Navarro-Compán V, Ramiro S, Landewé R, et al. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis 2016;75:874-8.
58. Machado P, Landewé RB, Braun J, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012;71:2002-5.
59. van der Heijde D, Sieper J, Maksymowych WP, et al. Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2014;66:667-73.
60. Kiltz U, Baraliakos X, Karakostas P, et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: A cohort study. Ann Rheum Dis 2012;71:1207-11.
61. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis 2015;74:954-62.
62. Sudre A, Figuereido IT, Lukas C, et al. On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. Joint Bone Spine 2012;79: 99-100.
63. Candelas G, Villaverde V, García S, et al. Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: A systematic literature review. Rheumatol Int 2016;36:1493-506.
64. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;(1):CD002822.
65. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis. Arthritis Rheum 2012;64:1388-98.
66. Ramiro S, Landewé R, van Tubergen A, et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: A longitudinal analysis. RMD Open 2015;1:e000153.
67. Chung HY, Machado P, van der Heijde D, et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012;71:809-16.
68. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101-7.
69. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5.
70. Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: A population-based study. Ann Intern Med 2015;163:409-16.
71. Wanders A, Heijde Dv, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
72. Kroon F, Landewé R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623-9.
73. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616-22.
74. Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016;75:1438-43.
75. van der Heijde D, Machado P, Braun J, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: A multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:369-73.
76. Machado PM, Baraliakos X, van der Heijde D, et al. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: A multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2016;75:1486-93.
77. Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-Term observational study using MRI and conventional radiography. Ann Rheum Dis 2014;73:1819-25.
78. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
79. Haibel H, Fendler C, Listing J, et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-Term trial. Ann Rheum Dis 2014;73:243-6.
80. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;(2):CD004800.
81. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006;(4):CD004524.
82. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial. Ann Rheum Dis 2007;66:419-21.
83. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-Alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study. Arthritis Res Ther 2011;13:R94.
84. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-Tumour necrosis factor: results from 8 years surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002-8.
85. Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-Tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-81.
86. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
87. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
88. Fagerli KM, Lie E, van der Heijde D, et al. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology (Oxford) 2012;51:1479-83.
89. Vastesaeger N, Cruyssen BV, Mulero J, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin 2014;10:204-9.
90. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
91. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014;371:326-38.
92. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-Tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
93. van Denderen JC, Visman IM, Nurmohamed MT, et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol 2014;41:1843-8.
94. Rudwaleit M, Rosenbaum JT, Landewé R, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken) 2016;68:838-44.
95. Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010;69: 226-9.
96. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121: 437-40.
97. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
98. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial. Gut 2007;56: 1232-9.
99. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohns disease. N Engl J Med 2007;357:228-38.
100. Song IH, Appel H, Haibel H, et al. New onset of Crohns disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008;35:532-6.
101. Adedokun OJ, Xu Z, Marano CW, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-To-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis 2016.
102. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 2011;70:157-63.
103. Yates M, Hamilton LE, Elender F, et al. Is Etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J Rheumatol 2015;42:1177-85.
104. Cantini F, Niccoli L, Cassarà E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: A randomized, prospective, long-Term, follow-up study. Biologics 2013;7:1-6.
105. Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212-15.
106. Haibel H, Heldmann F, Braun J, et al. Long-Term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum 2013;65:2211-13.
107. Vander Cruyssen B, Muñoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010;49:73-81.
108. Van Royen BJ, De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis 1999;58:399-406.
109. Westerveld LA, Verlaan JJ, Oner FC. Spinal fractures in patients with ankylosing spinal disorders: A systematic review of the literature on treatment, neurological status and complications. Eur Spine J 2009;18:145-56.
110. Mandl P, Navarro-Compán V, Terslev L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 2015;74:1327-39.
111. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71.
112. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2016;68:151-66.